MA5-11940
antibody from Invitrogen Antibodies
Targeting: CHEK2
bA444G7, CDS1, CHK2, HuCds1, PP1425, RAD53
Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-11940 - Provider product page

- Provider
- Invitrogen Antibodies
- Product name
- CHK2 Monoclonal Antibody (2CHK01 (DCS-293))
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Description
- MA5-11940 targets Chk2 in immunofluorescence, immunoprecipiation, and Western blot applications and shows reactivity with Human samples. The antibody does not react with Chk1. The MA5-11940 immunogen is recombinant Chk2 protein.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 2CHK01 (DCS-293)
- Vial size
- 500 μL
- Concentration
- 0.2 mg/mL
- Storage
- 4°C
Submitted references Ionizing radiation-dependent and independent phosphorylation of the 32-kDa subunit of replication protein A during mitosis.
Tumor suppressor protein C53 antagonizes checkpoint kinases to promote cyclin-dependent kinase 1 activation.
Polo-like kinase 1 and Chk2 interact and co-localize to centrosomes and the midbody.
CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas.
Stephan H, Concannon C, Kremmer E, Carty MP, Nasheuer HP
Nucleic acids research 2009 Oct;37(18):6028-41
Nucleic acids research 2009 Oct;37(18):6028-41
Tumor suppressor protein C53 antagonizes checkpoint kinases to promote cyclin-dependent kinase 1 activation.
Jiang H, Wu J, He C, Yang W, Li H
Cell research 2009 Apr;19(4):458-68
Cell research 2009 Apr;19(4):458-68
Polo-like kinase 1 and Chk2 interact and co-localize to centrosomes and the midbody.
Tsvetkov L, Xu X, Li J, Stern DF
The Journal of biological chemistry 2003 Mar 7;278(10):8468-75
The Journal of biological chemistry 2003 Mar 7;278(10):8468-75
CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas.
Tort F, Hernàndez S, Beà S, Martínez A, Esteller M, Herman JG, Puig X, Camacho E, Sánchez M, Nayach I, Lopez-Guillermo A, Fernández PL, Colomer D, Hernàndez L, Campo E
Blood 2002 Dec 15;100(13):4602-8
Blood 2002 Dec 15;100(13):4602-8
No comments: Submit comment
No validations: Submit validation data